Axel Nogai
Overview
Explore the profile of Axel Nogai including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
373
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Heck C, Steiner S, Kaebisch E, Frentsch M, Wittenbecher F, Scheibenbogen C, et al.
Front Immunol
. 2021 Oct;
12:736137.
PMID: 34659226
Introduction: High-dose chemotherapy followed by autologous hematopoietic stem cell transplantation (auto-HSCT) represents a standard treatment regime for multiple myeloma (MM) patients. Common and potentially fatal side effects after auto-HSCT are...
12.
Janjetovic S, Lohneis P, Nogai A, Balci D, Rasche L, Jahne D, et al.
Biology (Basel)
. 2021 Aug;
10(7).
PMID: 34356484
Extramedullary plasma cell (PC) disorders may occur as extramedullary disease in multiple myeloma (MM-EMD) or as primary extramedullary plasmocytoma (pEMP)/solitary osseous plasmocytoma (SOP). In this study, we aimed to obtain...
13.
Rambaldi A, Iurlo A, Vannucchi A, Martino B, Guarini A, Ruggeri M, et al.
Blood Cancer J
. 2021 Mar;
11(3):53.
PMID: 33677466
Polycythemia vera (PV) is a BCR-ABL1-negative myeloproliferative neoplasm (MPN) characterized by excessive proliferation of erythroid, myeloid, and megakaryocytic components in the bone marrow, mainly due to a Janus kinase 2...
14.
Goldschmidt H, Baertsch M, Schlenzka J, Becker N, Habermehl C, Hielscher T, et al.
Leukemia
. 2020 Jul;
35(4):1134-1144.
PMID: 32694619
The role of salvage high-dose chemotherapy and autologous stem cell transplantation (sHDCT/ASCT) for relapsed and/or refractory multiple myeloma (RRMM) in the era of continuous novel agent treatment has not been...
15.
Kiefer T, Krahl D, Kohlmann T, Nogai A, Baurmann H, Schuler F, et al.
Eur J Cancer Care (Engl)
. 2019 Dec;
29(2):e13201.
PMID: 31808982
Objective: Patients suffering from haemato-oncological diseases tend to have a weakened immune system after the end of their therapy. To avoid infections, patients are advised to limit contact with other...
16.
Baertsch M, Schlenzka J, Lisenko K, Krzykalla J, Becker N, Weisel K, et al.
Eur J Haematol
. 2017 Apr;
99(1):42-50.
PMID: 28370401
Objective: Analysis of the efficiency and toxicity of cyclophosphamide-based stem cell mobilization in patients with relapsed multiple myeloma (RMM). Methods: Peripheral blood stem cells (PBSCs) were mobilized with high dose...
17.
Nogai A, Shi Y, Perez-Hernandez D, Cordes S, Mengwasser J, Mertlitz S, et al.
Haematologica
. 2016 May;
101(8):e344-6.
PMID: 27198715
No abstract available.
18.
Baertsch M, Schlenzka J, Mai E, Merz M, Hillengass J, Raab M, et al.
BMC Cancer
. 2016 Apr;
16:290.
PMID: 27114074
Background: Despite novel therapeutic agents, most multiple myeloma (MM) patients eventually relapse. Two large phase III trials have shown significantly improved response rates (RR) of lenalidomide/dexamethasone compared with placebo/dexamethasone in...
19.
Berenstein R, Nogai A, Waechter M, Blau O, Kuehnel A, Schmidt-Hieber M, et al.
Mol Carcinog
. 2016 Mar;
55(12):1927-1939.
PMID: 27023728
Bone marrow mesenchymal stromal cells (BMMSCs) represent a crucial component of multiple myeloma (MM) microenvironment supporting its progression and proliferation. Recently, microRNAs have become an important point of interest for...
20.
Berenstein R, Blau O, Nogai A, Waechter M, Slonova E, Schmidt-Hieber M, et al.
BMC Cancer
. 2015 Apr;
15:68.
PMID: 25886144
Background: Alterations and senescence in bone marrow mesenchymal stromal cells of multiple myeloma patients (MM-BMMSCs) have become an important research focus. However the role of senescence in the pathophysiology of...